{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:59:38Z","timestamp":1785765578071,"version":"3.56.0"},"reference-count":41,"publisher":"American Chemical Society (ACS)","issue":"8","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Lipid nanoparticles (LNPs) are highly modular drug nanocarriers that have significantly progressed in the development and application of novel RNA therapeutics. While instrumental in current vaccine and hepatic gene therapy applications, extrahepatic LNP delivery remains a challenging hurdle, severely limiting clinical applications for individualized therapies that require cellular- and tissue-specific enrichment. Novel platform development remains needed to generate targeted LNPs capable of modeling targeted uptake in vitro prior to in vivo applications. Herein, we developed and utilized an antibody-based targeting bispecific-LNP (TbsAb-LNP) platform simultaneously binding LNP polyethylene glycol motifs and desired cell surface markers. By colocalizing TbsAb-LNP complexes with desired cell surface markers, we enable mRNA-LNP accumulation in the desired cell types. We additionally assessed the endosomal efficiency kinetics of TbsAb-LNP complexes generated at various bispecific loading ratios in a Galectin-9 in vitro expression model. Leveraging this facile and modular platform that eliminates the need for complex chemical conjugation approaches, we successfully achieved targeted LNP delivery to xhuCD3-expressing lymphoblasts and xmTfR1-expressing cell lines in vitro as well as xmTfR1-expressing cells in vivo. Enrichment of TbsAb-LNPs to splenic cells demonstrates the potential utility of this platform for clinical vaccine and T-cell delivery applications.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.6c00239","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T06:41:11Z","timestamp":1784529671000},"page":"4190-4202","source":"Crossref","is-referenced-by-count":0,"title":["Targeted\nmRNA Delivery Using Bispecific Antibody-Lipid\nNanoparticle Complexes"],"prefix":"10.1021","volume":"23","author":[{"given":"James Collin","family":"Hickey","sequence":"first","affiliation":[{"name":"Pfizer Inc. , , , ,","place":["Cambridge, Massachusetts, United States, 02139"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracoyia","family":"Roach","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , , , ,","place":["Cambridge, Massachusetts, United States, 02139"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britteny","family":"Cassaidy","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , , , ,","place":["Groton, Connecticut, United States, 06340"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Hergesheimer","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , , , ,","place":["La Jolla, California, United States, 92121"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Franklin","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , , , ,","place":["Cambridge, Massachusetts, United States, 02139"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Morin","sequence":"additional","affiliation":[{"name":"Pfizer Inc , , , ,","place":["Cambridge, Massachusetts, United States, 02139"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Wagman","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , , , ,","place":["Cambridge, Massachusetts, United States, 02139"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Cohen","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , , , ,","place":["Cambridge, Massachusetts, United States, 02139"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Morrissey","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , , , ,","place":["Cambridge, Massachusetts, United States, 02139"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Chaparro-Riggers","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , , , ,","place":["La Jolla, California, United States, 92121"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3477-9222","authenticated-orcid":true,"given":"Patrick","family":"Lim Soo","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , , , ,","place":["Andover, Massachusetts, United States, 01810"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"issue":"12","key":"2026080309081191100_cit1","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles\nfor mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"issue":"3","key":"2026080309081191100_cit2","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3390\/vaccines11030658","article-title":"Recent Advances in the Lipid Nanoparticle-Mediated\nDelivery of mRNA Vaccines","volume":"11","author":"Swetha","year":"2023","journal-title":"Vaccines"},{"key":"2026080309081191100_cit3","doi-asserted-by":"publisher","first-page":"103041","DOI":"10.1016\/j.copbio.2023.103041","article-title":"Biological recognition\nand cellular trafficking of targeted RNA-lipid nanoparticles","volume":"85","author":"Escalona-Rayo","year":"2024","journal-title":"Curr. Opin. Biotechnol."},{"key":"2026080309081191100_cit4","doi-asserted-by":"publisher","first-page":"120586","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19\nvaccines: Structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"5","key":"2026080309081191100_cit5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety\nof the mRNA-1273 SARS-CoV-2\nVaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"2026080309081191100_cit6","doi-asserted-by":"publisher","first-page":"103699","DOI":"10.1016\/j.ebiom.2021.103699","article-title":"Current\nand future\nnanoparticle vaccines for COVID-19","volume":"74","author":"Vu","year":"2021","journal-title":"EBioMedicine"},{"issue":"10309","key":"2026080309081191100_cit7","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","article-title":"Effectiveness\nof mRNA BNT162b2 COVID-19 vaccine up\nto 6 months in a large integrated health system in the USA: a retrospective\ncohort study","volume":"398","author":"Tartof","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"2026080309081191100_cit8","doi-asserted-by":"publisher","first-page":"102083","DOI":"10.1016\/j.omtn.2023.102083","article-title":"mRNA vaccine trafficking and resulting\nprotein expression after intramuscular administration","volume":"35","author":"Hassett","year":"2024","journal-title":"Mol. Ther.\u2500Nucleic Acids"},{"key":"2026080309081191100_cit9","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2013.66","article-title":"Influence\nof Polyethylene Glycol Lipid Desorption\nRates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles","volume":"2","author":"Mui","year":"2013","journal-title":"Mol. Ther.\u2500Nucleic Acids"},{"issue":"4","key":"2026080309081191100_cit10","doi-asserted-by":"publisher","first-page":"6709","DOI":"10.1021\/acsnano.0c10064","article-title":"Apolipoprotein E Binding\nDrives Structural and Compositional Rearrangement of mRNA-Containing\nLipid Nanoparticles","volume":"15","author":"Sebastiani","year":"2021","journal-title":"ACS Nano"},{"issue":"7","key":"2026080309081191100_cit11","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted Delivery of RNAi Therapeutics With\nEndogenous and Exogenous Ligand-Based Mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol. Ther."},{"issue":"2","key":"2026080309081191100_cit12","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1021\/mp500400k","article-title":"Real Time Measurement of PEG Shedding from Lipid Nanoparticles\nin Serum via NMR Spectroscopy","volume":"12","author":"Wilson","year":"2015","journal-title":"Mol. Pharmaceutics"},{"issue":"7","key":"2026080309081191100_cit13","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3390\/ph15070897","article-title":"The Future\nof Tissue-Targeted Lipid\nNanoparticle-Mediated Nucleic Acid Delivery","volume":"15","author":"Kularatne","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"2026080309081191100_cit14","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective\norgan targeting (SORT) nanoparticles for tissue-specific mRNA delivery\nand CRISPR\u2013Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"issue":"52","key":"2026080309081191100_cit15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2109256118","article-title":"On the\nmechanism of tissue-specific\nmRNA delivery by selective organ targeting nanoparticles","volume":"118","author":"Dilliard","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"13","key":"2026080309081191100_cit16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2319856121","article-title":"IL7 increases targeted\nlipid nanoparticle\u2013mediated mRNA expression in T cells in vitro\nand in vivo by enhancing T cell protein translation","volume":"121","author":"Tilsed","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"2026080309081191100_cit17","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011759","article-title":"T cell-specific non-viral\nDNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles","volume":"13","author":"Bimbo","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"2026080309081191100_cit18","doi-asserted-by":"publisher","first-page":"114365","DOI":"10.1016\/j.jconrel.2025.114365","article-title":"Cell-specific mRNA delivery via nanobody-functionalized\nlipid nanoparticles","volume":"388","author":"Chen","year":"2025","journal-title":"J. Controlled Release"},{"issue":"6656","key":"2026080309081191100_cit19","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1126\/science.ade6967","article-title":"In\nvivo hematopoietic stem cell modification\nby mRNA delivery","volume":"381","author":"Breda","year":"2023","journal-title":"Science"},{"issue":"6576","key":"2026080309081191100_cit20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR\nT cells produced\nin vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"2026080309081191100_cit21","doi-asserted-by":"publisher","first-page":"121339","DOI":"10.1016\/j.biomaterials.2021.121339","article-title":"In\nsitu T-cell transfection by anti-CD3-conjugated lipid nanoparticles\nleads to T-cell activation, migration, and phenotypic shift","volume":"281","author":"Kheirolomoom","year":"2022","journal-title":"Biomaterials"},{"key":"2026080309081191100_cit22","doi-asserted-by":"publisher","first-page":"102518","DOI":"10.1016\/j.nantod.2024.102518","article-title":"In situ\nengineering of mRNA-CAR T cells using spleen-targeted\nionizable lipid nanoparticles to eliminate cancer cells","volume":"59","author":"Li","year":"2024","journal-title":"Nano Today"},{"key":"2026080309081191100_cit23","doi-asserted-by":"publisher","first-page":"102043","DOI":"10.1016\/j.omtn.2023.102043","article-title":"Induction of long-term tolerance\nto a specific antigen using anti-CD3 lipid nanoparticles following\ngene therapy","volume":"34","author":"Chen","year":"2023","journal-title":"Mol. Ther.\u2500Nucleic Acids"},{"issue":"2","key":"2026080309081191100_cit24","doi-asserted-by":"publisher","first-page":"102520","DOI":"10.1016\/j.omtn.2025.102520","article-title":"Targeted mRNA delivery with bispecific\nantibodies that\ntether LNPs to cell surface markers","volume":"36","author":"Dietmair","year":"2025","journal-title":"Mol. Ther.\u2500Nucleic\nAcids"},{"key":"2026080309081191100_cit25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.freeradbiomed.2018.06.037","article-title":"Transferrin\nand transferrin receptors update","volume":"133","author":"Kawabata","year":"2019","journal-title":"Free Radical\nBiol. Med."},{"issue":"3","key":"2026080309081191100_cit26","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.bbagen.2011.09.009","article-title":"The intracellular\ntrafficking pathway\nof transferrin","volume":"1820","author":"Mayle","year":"2012","journal-title":"Biochim. Biophys. Acta Gen.\nSubj."},{"issue":"4","key":"2026080309081191100_cit27","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1124\/pr.54.4.561","article-title":"Targeted Drug Delivery via the Transferrin\nReceptor-Mediated Endocytosis Pathway","volume":"54","author":"Qian","year":"2002","journal-title":"Pharmacol.\nRev."},{"issue":"1","key":"2026080309081191100_cit28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s43856-025-00733-w","article-title":"FORCE platform overcomes barriers of oligonucleotide delivery to\nmuscle and corrects myotonic dystrophy features in preclinical models","volume":"5","author":"Weeden","year":"2025","journal-title":"Commun. Med."},{"issue":"12","key":"2026080309081191100_cit29","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1093\/nar\/gkad415","article-title":"Targeted\ntissue delivery of RNA therapeutics\nusing antibody\u2013oligonucleotide conjugates (AOCs)","volume":"51","author":"Malecova","year":"2023","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"2026080309081191100_cit30","doi-asserted-by":"publisher","first-page":"4493","DOI":"10.1038\/s41467-018-06936-1","article-title":"Cell specific delivery of modified mRNA expressing therapeutic proteins\nto leukocytes","volume":"9","author":"Veiga","year":"2018","journal-title":"Nat. Commun."},{"issue":"9","key":"2026080309081191100_cit31","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/s41565-025-01954-9","article-title":"A versatile antibody\ncapture system drives specific\nin vivo delivery of mRNA-loaded lipid nanoparticles","volume":"20","author":"Chen","year":"2025","journal-title":"Nat. Nanotechnol."},{"key":"2026080309081191100_cit32","doi-asserted-by":"publisher","first-page":"123990","DOI":"10.1016\/j.ijpharm.2024.123990","article-title":"Enhancing precision\nmedicine: Bispecific antibody-mediated targeted delivery of lipid\nnanoparticles for potential cancer therapy","volume":"654","author":"Zhang","year":"2024","journal-title":"Int. J. Pharm."},{"issue":"1","key":"2026080309081191100_cit33","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s42004-020-00369-y","article-title":"Structure\nof an anti-PEG antibody\nreveals an open ring that captures highly flexible PEG polymers","volume":"3","author":"Huckaby","year":"2020","journal-title":"Commun. Chem."},{"issue":"9","key":"2026080309081191100_cit34","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1158\/1078-0432.CCR-19-3275","article-title":"A Novel\nGUCY2C-CD3 T-Cell Engaging Bispecific Construct\n(PF-07062119) for the Treatment of Gastrointestinal Cancers","volume":"26","author":"Mathur","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"2026080309081191100_cit35","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/bit.22135","article-title":"Engineering\nand expression of a chimeric transferrin receptor monoclonal antibody\nfor blood\u2013brain barrier delivery in the mouse","volume":"102","author":"Boado","year":"2009","journal-title":"Biotechnol. Bioeng."},{"issue":"1","key":"2026080309081191100_cit36","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s42003-021-01728-8","article-title":"A high-throughput Galectin-9 imaging\nassay for quantifying nanoparticle uptake, endosomal escape and functional\nRNA delivery","volume":"4","author":"Munson","year":"2021","journal-title":"Commun. Biol."},{"issue":"19","key":"2026080309081191100_cit37","doi-asserted-by":"publisher","first-page":"9793","DOI":"10.3390\/ijms26199793","article-title":"Targeting Transferrin\nReceptor 1 for Enhancing Drug Delivery Through the Blood\u2013Brain\nBarrier for Alzheimer\u2019s Disease","volume":"26","author":"Shen","year":"2025","journal-title":"Int.\nJ. Mol. Sci."},{"issue":"9","key":"2026080309081191100_cit38","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","article-title":"A Single Administration of CRISPR\/Cas9 Lipid Nanoparticles\nAchieves Robust and Persistent In Vivo Genome Editing","volume":"22","author":"Finn","year":"2018","journal-title":"Cell Rep."},{"issue":"1","key":"2026080309081191100_cit39","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12987-025-00643-y","article-title":"The effects\nof dose, valency, and\naffinity on TfR-mediated brain delivery in vivo","volume":"22","author":"Bonvicini","year":"2025","journal-title":"Fluids Barriers CNS"},{"issue":"1","key":"2026080309081191100_cit40","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12987-021-00257-0","article-title":"Brain pharmacokinetics\nof two BBB penetrating bispecific\nantibodies of different size","volume":"18","author":"Faresjo\u0308","year":"2021","journal-title":"Fluids Barriers\nCNS"},{"issue":"7","key":"2026080309081191100_cit41","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1073\/pnas.0608582104","article-title":"Understanding\nthe nanoparticle\u2013protein corona using methods to quantify exchange\nrates and affinities of proteins for nanoparticles","volume":"104","author":"Cedervall","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.6c00239","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/8\/4190\/66035613\/acs.molpharmaceut.6c00239.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/8\/4190\/66035613\/acs.molpharmaceut.6c00239.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:13:42Z","timestamp":1785762822000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/23\/8\/4190\/5215858\/Targeted-mRNA-Delivery-Using-Bispecific-Antibody"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":41,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,7,20]]},"published-print":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6c00239","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]}}}